Dynamic Cell Therapies is venture capital backed and based in Boston, MA. DCT is in the pre-clinical phase of developing controllable CAR-T cells to address difficult-to-treat cancers. Its platform technology of dynamic control of engineered T-cells is designed to improve the safety, efficacy, and durability of CAR-T cell therapies. This system should find initial applications in hematological cancers, with future approaches in solid tumors and autoimmune diseases. The company’s platform technology uncouples tumor targeting from CAR-T cell activation. Each CAR-T cell recognizes an inert small molecule. This small molecule is conjugated to a tumor-specific antibody. By dosing a small molecule-antibody conjugate, the physician could dynamically control CAR-T cell activity and potentially minimize the risk of life-threatening side effects. Increasing the dose of the small molecule-antibody conjugate should strengthen the immune attack against tumor cells. In addition, the same small molecule can be coupled to different tumor targeting antibodies, allowing the physician to maximize on-target on-tumor efficacy and reduce off-tumor toxicities. To learn more, please visit www.dynamiccelltherapies.com.

https://www.dynamiccelltherapies.com/

Dynamic Cell Therapies

Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

https://atossatherapeutics.com/

Seattle

Atossa Therapeutics

Atossa Therapeutics, Inc. (Nasdaq: ATOS), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (DCT). Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments.

Atossa Therapeutics, Inc. To Acquire Stake In Privately Held Dynamic Cell Therapies As Part Of Overall Car-T Strategy

Atossa Therapeutics, Inc. To Acquire Stake In Privately Held Dynamic Cell Therapies As Part Of Overall Car-T Strategy

Company Info

Related People